<span item_type="fundamental" item_id="b976075313e6e204abacaf9b12e42e38" counter_id="ST/US/PETVW" env="prod"></span><span item_type="announcement" item_id="536773831103088513" env="prod"></span><p>Revenue: As of FY2025, the actual value is USD 1.133 M.</p><p>EPS: As of FY2025, the actual value is USD -0.41.</p><p>EBIT: As of FY2025, the actual value is USD -8.056 M.</p><p></p><h3>Segment Revenue</h3><ul><li>Total revenue for the fiscal year ended March 31, 2025, was $1,132,533, compared to $968,706 for the fiscal year ended March 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1512922/000164117225018617/form10-k.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>Operating expenses decreased to $9,050,575 in fiscal 2025 from $11,488,223 in fiscal 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1512922/000164117225018617/form10-k.htm"></span></li><li>Net loss for fiscal 2025 was $8,399,166, compared to $10,955,295 in fiscal 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1512922/000164117225018617/form10-k.htm"></span></li><li>Gross profit for fiscal 2025 was $994,856, compared to $866,883 in fiscal 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1512922/000164117225018617/form10-k.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Net cash used in operating activities was $5,321,953 for fiscal 2025, compared to $7,419,588 for fiscal 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1512922/000164117225018617/form10-k.htm"></span></li><li>Net cash used in investing activities was $563,434 for fiscal 2025, compared to $309,104 for fiscal 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1512922/000164117225018617/form10-k.htm"></span></li><li>Net cash provided by financing activities was $6,025,673 for fiscal 2025, compared to $7,340,781 for fiscal 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1512922/000164117225018617/form10-k.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>The Company signed an exclusive licensing agreement with VetStem, Inc. to market and sell their Precise PRP (Platelet-Rich Plasma) product for both canine and equine, with revenues expected in fiscal year 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1512922/000164117225018617/form10-k.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>The Company anticipates that it will have sufficient cash to meet its anticipated operating costs and capital expenditure requirements for at least the next three months.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1512922/000164117225018617/form10-k.htm"></span></li><li>The Company expects to continue to raise additional capital through the sale of its securities from time to time for the foreseeable future to fund its business expansion.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1512922/000164117225018617/form10-k.htm"></span></li><li>The Company plans to increase its commercialization efforts of Spryng® in the United States through the use of sales reps, clinical studies, and market awareness.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1512922/000164117225018617/form10-k.htm"></span></li></ul>

PETVIVO HLDGS INC C/WTS 13/08/2026 (TO PUR COM) | 10-K: FY2025 Revenue: USD 1.133 M